Russell Investments Group Ltd. Raises Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Russell Investments Group Ltd. lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 36.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 290,228 shares of the medical device company’s stock after acquiring an additional 77,594 shares during the quarter. Russell Investments Group Ltd.’s holdings in Tandem Diabetes Care were worth $10,454,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TNDM. JPMorgan Chase & Co. raised its stake in Tandem Diabetes Care by 134.6% in the third quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company’s stock worth $8,379,000 after buying an additional 113,355 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock worth $65,000 after acquiring an additional 1,101 shares in the last quarter. US Bancorp DE lifted its stake in shares of Tandem Diabetes Care by 15.2% during the 4th quarter. US Bancorp DE now owns 38,708 shares of the medical device company’s stock worth $1,394,000 after purchasing an additional 5,108 shares during the last quarter. KBC Group NV lifted its stake in shares of Tandem Diabetes Care by 41.5% during the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company’s stock worth $6,933,000 after purchasing an additional 56,461 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its position in Tandem Diabetes Care by 22.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 1,184 shares in the last quarter.

Tandem Diabetes Care Stock Performance

TNDM opened at $17.06 on Friday. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The firm has a 50 day moving average of $23.62 and a two-hundred day moving average of $30.91. The firm has a market capitalization of $1.13 billion, a PE ratio of -8.84 and a beta of 1.52.

Analyst Upgrades and Downgrades

TNDM has been the subject of several analyst reports. The Goldman Sachs Group decreased their price target on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Canaccord Genuity Group reissued a “buy” rating and set a $63.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Royal Bank of Canada decreased their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Robert W. Baird lowered their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average price target of $43.88.

Insider Transactions at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares of the company’s stock, valued at $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.